T Cerny1, M Schwarz2, U Schwarz3, J Lemant4, P Gérardin5,6, E Keller7. 1. Neurointensive Care Unit, University Hospital Zurich, Frauenklinikstrasse 10, 8091, Zurich, Switzerland. 2. Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 3. Department of Neurology, University Hospital Zurich, Zurich, Switzerland. 4. Intensive Care Unit, CHU de la Réunion, Saint Pierre, Réunion, France. 5. INSERM CIC 1410, CHU de la Réunion, Saint Pierre, Réunion, France. 6. CNRS 9192, INSERM U1187, IRD 249, CHU Réunion, Unité Mixte 134 Processus Infectieux en Milieu Insulaire Tropical (PIMIT), CYROI, Université de La Réunion, Sainte-Clotilde, Réunion, France. 7. Neurointensive Care Unit, University Hospital Zurich, Frauenklinikstrasse 10, 8091, Zurich, Switzerland. emanuela.keller@usz.ch.
Abstract
BACKGROUND: Chikungunya fever is a globally spreading mosquito-borne disease that shows an unexpected neurovirulence. Even though the neurological complications have been a major cause of intensive care unit admission and death, to date, there is no systematic analysis of their spectrum available. OBJECTIVE: To review evidence of neurological manifestations in Chikungunya fever and map their epidemiology, clinical spectrum, pathomechanisms, diagnostics, therapies and outcomes. METHODS: Case report and systematic review of the literature followed established guidelines. All cases found were assessed using a 5-step clinical diagnostic algorithm assigning categories A-C, category A representing the highest level of quality. Only A and B cases were considered for further analysis. After general analysis, cases were clustered according to geospatial criteria for subgroup analysis. RESULTS: Thirty-six of 1196 studies were included, yielding 130 cases. Nine were ranked as category A (diagnosis of Neuro-Chikungunya probable), 55 as B (plausible), and 51 as C (disputable). In 15 cases, alternative diagnoses were more likely. Patient age distribution was bimodal with a mean of 49 years and a second peak in infants. Fifty percent of the cases occurred in patients <45 years with no reported comorbidity. Frequent diagnoses were encephalitis, optic neuropathy, neuroretinitis, and Guillain-Barré syndrome. Neurologic conditions showing characteristics of a direct viral pathomechanism showed a peak in infants and a second one in elder patients, and complications and neurologic sequelae were more frequent in these groups. Autoimmune-mediated conditions appeared mainly in patients over 20 years and tended to show longer latencies and better outcomes. Geospatial subgrouping of case reports from either India or Réunion revealed diverging phenotypic trends (Réunion: 88% direct viral vs. India: 81% autoimmune). CONCLUSIONS: Direct viral forms of Neuro-Chikungunya seem to occur particularly in infants and elderly patients, while autoimmune forms have to be also considered in middle-aged, previously healthy patients, especially after an asymptomatic interval. This knowledge will help to identify future Neuro-Chikungunya cases and to improve outcome especially in autoimmune-mediated conditions. The genetics of Chikungunya virus might play a key role in determining the course of neuropathogenesis. With further research, this could prove diagnostically significant.
BACKGROUND:Chikungunya fever is a globally spreading mosquito-borne disease that shows an unexpected neurovirulence. Even though the neurological complications have been a major cause of intensive care unit admission and death, to date, there is no systematic analysis of their spectrum available. OBJECTIVE: To review evidence of neurological manifestations in Chikungunya fever and map their epidemiology, clinical spectrum, pathomechanisms, diagnostics, therapies and outcomes. METHODS: Case report and systematic review of the literature followed established guidelines. All cases found were assessed using a 5-step clinical diagnostic algorithm assigning categories A-C, category A representing the highest level of quality. Only A and B cases were considered for further analysis. After general analysis, cases were clustered according to geospatial criteria for subgroup analysis. RESULTS: Thirty-six of 1196 studies were included, yielding 130 cases. Nine were ranked as category A (diagnosis of Neuro-Chikungunya probable), 55 as B (plausible), and 51 as C (disputable). In 15 cases, alternative diagnoses were more likely. Patient age distribution was bimodal with a mean of 49 years and a second peak in infants. Fifty percent of the cases occurred in patients <45 years with no reported comorbidity. Frequent diagnoses were encephalitis, optic neuropathy, neuroretinitis, and Guillain-Barré syndrome. Neurologic conditions showing characteristics of a direct viral pathomechanism showed a peak in infants and a second one in elder patients, and complications and neurologic sequelae were more frequent in these groups. Autoimmune-mediated conditions appeared mainly in patients over 20 years and tended to show longer latencies and better outcomes. Geospatial subgrouping of case reports from either India or Réunion revealed diverging phenotypic trends (Réunion: 88% direct viral vs. India: 81% autoimmune). CONCLUSIONS: Direct viral forms of Neuro-Chikungunya seem to occur particularly in infants and elderly patients, while autoimmune forms have to be also considered in middle-aged, previously healthy patients, especially after an asymptomatic interval. This knowledge will help to identify future Neuro-Chikungunya cases and to improve outcome especially in autoimmune-mediated conditions. The genetics of Chikungunya virus might play a key role in determining the course of neuropathogenesis. With further research, this could prove diagnostically significant.
Authors: Trina Das; Jean Jacques Hoarau; Marie Christine Jaffar Bandjee; Marianne Maquart; Philippe Gasque Journal: J Gen Virol Date: 2014-10-28 Impact factor: 3.891
Authors: Babasaheb V Tandale; Padmakar S Sathe; Vidya A Arankalle; R S Wadia; Rahul Kulkarni; Sudhir V Shah; Sanjeev K Shah; Jay K Sheth; A B Sudeep; Anuradha S Tripathy; Akhilesh C Mishra Journal: J Clin Virol Date: 2009-07-28 Impact factor: 3.168
Authors: Dominik Fischer; Stephanie M Thomas; Jonathan E Suk; Bertrand Sudre; Andrea Hess; Nils B Tjaden; Carl Beierkuhnlein; Jan C Semenza Journal: Int J Health Geogr Date: 2013-11-12 Impact factor: 3.918
Authors: Raíza Nara Cunha Moizéis; Thales Allyrio Araújo de Medeiros Fernandes; Paulo Marcos da Matta Guedes; Hannaly Wana Bezerra Pereira; Daniel Carlos Ferreira Lanza; Judson Welber Veríssimo de Azevedo; Josélio Maria de Araújo Galvão; José Veríssimo Fernandes Journal: Pathog Glob Health Date: 2018-05-28 Impact factor: 2.894
Authors: D G Corrêa; T A L Freddi; H Werner; F P P L Lopes; M E L Moreira; F C P de Almeida Di Maio Ferreira; J M de Andrade Lopes; F C Rueda-Lopes; L C H da Cruz Journal: AJNR Am J Neuroradiol Date: 2019-12-05 Impact factor: 3.825
Authors: Vanessa P Silva; Dacylla S Costa; Vania C C V L Carvalho; Tereza C C S Garcês; Emanuela L T Barros; Jefferson S Oliveira; Anna C T C Pereira; Gustavo P Ferreira Journal: J Neurovirol Date: 2019-08-19 Impact factor: 3.739
Authors: Doris K Nyamwaya; Mark Otiende; Lilian Mwango; Symon M Kariuki; Berrick Otieno; Donwilliams O Omuoyo; George Githinji; Barnes S Kitsao; Henry K Karanja; John N Gitonga; Zaydah R de Laurent; Alun Davies; Salim Mwarumba; Charles N Agoti; Samuel M Thumbi; Mainga M Hamaluba; Charles R Newton; Philip Bejon; George M Warimwe Journal: PLoS Med Date: 2022-05-12 Impact factor: 11.613
Authors: Ravi Mehta; Patrick Gerardin; Carlos Alexandre Antunes de Brito; Cristiane Nascimento Soares; Maria Lucia Brito Ferreira; Tom Solomon Journal: Rev Med Virol Date: 2018-04-19 Impact factor: 6.989
Authors: Maira Sant Anna Genaro; Micheli Said de Marchi; Matheus Yung Perin; Isabelle Silva Cossô; Renata Dezengrini Slhessarenko Journal: Am J Trop Med Hyg Date: 2020-11 Impact factor: 2.345